Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PP1493
- Development stage
- Unknown
- Lead developer
- PHAXIAM Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intraarticular, Intravenous
01
Overview
PP1493 is a bacteriophage cocktail developed by Phaxiam Therapeutics (formed by the merger of Pherecydes Pharma and Erytech Pharma) for the treatment of infections caused by *Staphylococcus aureus*, specifically targeting prosthetic joint infections (PJI). The therapy consists of a cocktail of three lytic bacteriophages selected for their broad host range and high activity against various *S. aureus* strains, including methicillin-resistant *Staphylococcus aureus* (MRSA). Bacteriophages are viruses that specifically infect and kill bacteria without affecting human cells or the commensal microbiome. PP1493 is designed to be used as an adjunct to standard-of-care surgical debridement and antibiotic therapy, particularly in cases where bacterial biofilms make conventional antibiotics less effective. It is currently being evaluated in clinical trials, including the Phase 2 PHAGEINLY study.
- Other names
- anti-Staphylococcus aureus bacteriophagesPhaxiam S. aureus phage cocktail
Beyond the preview
Go deeper on PP1493.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PP1493.